The U.S. FDA approves expanded access to daraxonrasib, a breakthrough targeted therapy for previously treated metastatic pancreatic ductal adenocarcinoma, offering new hope for patients with one of the deadliest cancers.
The US FDA approves expanded access to daraxonrasib, an innovative pancreatic cancer drug, offering new hope for patients facing one of the deadliest forms of cancer.
The FDA approves an expanded access program for daraxonrasib, an innovative pancreatic cancer drug that showed promising results in clinical trials, offering new hope for patients with one of the most challenging cancers.
The U.S. FDA approves expanded early access for the experimental pancreatic cancer drug daraxonrasib, offering new hope for late-stage patients.